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Abstract
Protection against virulent pathogens that cause acute, fatal disease is often hampered by development of microbial
resistance to traditional chemotherapeutics. Further, most successful pathogens possess an array of immune evasion
strategies to avoid detection and elimination by the host. Development of novel, immunomodulatory prophylaxes that
target the host immune system, rather than the invading microbe, could serve as effective alternatives to traditional
chemotherapies. Here we describe the development and mechanism of a novel pan-anti-bacterial prophylaxis. Using
cationic liposome non-coding DNA complexes (CLDC) mixed with crude F. tularensis membrane protein fractions (MPF), we
demonstrate control of virulent F. tularensis infection in vitro and in vivo. CLDC+MPF inhibited bacterial replication in
primary human and murine macrophages in vitro. Control of infection in macrophages was mediated by both reactive
nitrogen species (RNS) and reactive oxygen species (ROS) in mouse cells, and ROS in human cells. Importantly, mice treated
with CLDC+MPF 3 days prior to challenge survived lethal intranasal infection with virulent F. tularensis. Similarly to in vitro
observations, in vivo protection was dependent on the presence of RNS and ROS. Lastly, CLDC+MPF was also effective at
controlling infections with Yersinia pestis, Burkholderia pseudomallei and Brucella abortus. Thus, CLDC+MPF represents a
novel prophylaxis to protect against multiple, highly virulent pathogens.
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Introduction
Historically, control of bacterial infections has been dependent
on administration of antibiotics. However, with many acute,
lethal, bacterial infections, e.g. those mediated by Francisella
tularensis, Yersinia pestis and Staphylococcus aureus, diagnosis and
timely administration of appropriate antibiotics represents a
significant hurdle in successful treatment of disease mediated by
these pathogens. Further, mass administration of prophylactic
antibiotics in an outbreak situation may result in the generation of
antibiotic resistant strains, rendering this treatment ineffective for
both ongoing infections and future outbreaks. Thus, there is a
need for novel, broad spectrum, prophylaxis against highly
pathogenic bacterial infections.
F. tularensis is a Gram negative, facultative intracellular
bacterium and the causative agent of Tularemia. F. tularensis is
extremely infectious, capable of causing acute, lethal, disease
following inhalation of as few as 10–15 bacteria [1,2]. Currently,
there is no vaccine approved for use against F. tularensis. Although
antibiotic therapy can successfully treat pneumonic Tularemia,
therapy must be initiated within the first few days following the
onset of symptoms when individuals are often unaware of the
severity of their infection [3]. Furthermore, treatment with
antibiotics can fail to adequately clear F. tularensis, resulting in
recrudescence of infection once antibiotic therapy ends [4,5,6].
A number of studies have described development of novel anti-
microbials that target the host immune response rather than the
invading pathogen [7,8,9]. These immunotherapeutics target host
pathways which either directly activate effector cells or relieve
pathogen induced suppression of host killing mechanisms,
resulting in control and elimination of a wide variety of
microorganisms. In the case of intracellular pathogens such as F.
tularensis, targeting host effector mechanisms is appealing since
some antibiotics preferred for treatment of Tularemia, e.g.
gentamicin, poorly permeate the host cell and therefore fail to
reach the targeted organism. Activation of host effector cells
capable of killing intracellular pathogens with novel immunother-
apeutics or prophylaxes represents a viable alternative, or
supplement, to exiting chemotherapy.
In this report we describe a novel anti-microbial comprised of
cationic liposome DNA complexes (CLDC) and crude membrane
protein fraction (MPF) derived from attenuated F. tularensis strain
LVS. CLDC+MPF effectively controlled in vivo and in vitro
infections of virulent F. tularensis strain SchuS4 in mouse and
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MPF was critical for mediating this protection, since treatment
with CLDC or MPF alone failed to attenuate F. tularensis
replication and pathogenicity. The dramatic control of F. tularensis
infection mediated by CLDC+MPF was dependent on stimulation
of both reactive oxygen and nitrogen species (ROS and RNS,
respectively) in vivo and in vitro. Finally, we demonstrate that
CLDC+MPF was also an effective antimicrobial against three
other important bacteria, Burkholderia pseudomallei, Yersinia pestis and
Brucella abortus. Thus, data presented herein represents an
important step toward development of novel, efficacious, broad
spectrum, antimicrobial therapy directed against highly patho-
genic microbes.
Results
CLDC+MPF controlled replication of SchuS4 in mouse
and human cells
To establish the anti-microbial potential of CLDC+MPF we
first examined the effect of this compound on the infection and
replication of SchuS4 in mouse and human macrophages. Cells
were treated with either 5% dextrose water (D5W;untreated),
CLDC, MPF or CLDC+MPF approximately 18 h prior to
SchuS4 infection. At the indicated time points, viable intracellular
bacteria were enumerated. Macrophages treated with MPF or
CLDC alone failed to control SchuS4 replication (Table 1 and 2).
Additionally, treatment of mouse macrophages with MPF or
CLDC alone exacerbated SchuS4 replication in these cells
(Table 1). In contrast to cells treated with the individual
components or untreated controls, cells pre-treated with
CLDC+MPF had significantly fewer intracellular bacteria
(Table 1 and 2). It was possible that treatment with CLDC+MPF
induced cell death which in turn resulted in smaller numbers of
intracellular SchuS4. However, staining by trypan blue revealed
that, similar to untreated controls, greater than 90% of
CLDC+MPF treated macrophages were viable at the time of
infection (Figure S1). Thus, generalized cell death could not
account for the reduction in bacterial loads following CLDC+MPF
treatment. Together this data shows that while CLDC+MPF did
not limit uptake of SchuS4, it did control replication of the
intracellular bacterium.
Intracellular replication of SchuS4 in macrophages is dependent
on their ability to escape the phagolysosome within the first hour
of infection [10]. Thus, although CLDC+MPF did not appear to
alter the initial uptake of SchuS4 by macrophages, it was possible
that this mixture inhibited the ability of SchuS4 to escape the
phagolysosome subsequently resulting in killing of the bacterium.
Phagosomal escape by SchuS4 can be measured by microscopy by
the loss of LAMP-1 colocalization with the bacterium following
macrophage phagocytosis [10]. To assess the effect CLDC, MPF
and CLDC+MPF had on SchuS4 phagosomal escape we next
examined co-localization of SchuS4 with LAMP-1 in treated
mouse and human macrophages 24 h after infection by micros-
copy. As described above, CLDC+MPF did not significantly alter
the number of bacteria phagocytosed by either mouse or human
macrophages compared to untreated controls (Figure 1B and 2B,
respectively). Further, CLDC+MPF treatment did not inhibit the
ability of SchuS4 to escape into the cytosol of infected cells as
evident by the absence of SchuS4 co-localization with LAMP-1
4 hours after infection in all treatment groups (Figure 1A and 2A).
In contrast, CLDC+MPF significantly reduced the number of
infected human and mouse macrophages 24 h after infection
(Figures 1A, C and 2A, C, respectively). We also examined if
CLDC+MPF mediated killing of SchuS4 by electron microscopy.
As expected, in untreated cells SchuS4 was present as intact
bacteria in the cytosol (Figure S2). In contrast, bacteria present in
Table 1. CLDC+MPF controls replication of F. tularensis
SchuS4 in mouse macrophages.
Treatment
Time after
Infection (hours) CFU/ml (log10)±SEM
untreated 3 2.1360.09
CLDC 3 3.1660.13
MPF 3 3.3460.13
CLDC+MPF 3 3.1060.09
untreated 24 3.3060.23
CLDC 24 5.3060.01
MPF 24 4.7260.19
CLDC+MPF 24 1.6060.35
doi:10.1371/journal.ppat.1000921.t001
Table 2. CLDC+MPF controls replication in F. tularensis
SchuS4 in human macrophages.
Treatment
Time after
Infection (hours) CFU/ml (log10) ±SEM
untreated 3 2.8460.09
CLDC 3 2.7660.03
MPF 3 3.0160.02
CLDC+MPF 3 2.4960.01
untreated 24 4.8860.05
CLDC 24 4.5660.09
MPF 24 4.6160.02
CLDC+MPF 24 3.4260.30
doi:10.1371/journal.ppat.1000921.t002
Author Summary
Conventional treatment of bacterial infections typically
includes administration of antibiotics. However, many
pathogens have developed spontaneous resistance to
commonly used antibiotics. Development of new com-
pounds that stimulate the host immune system to directly
kill bacteria by mechanisms different from those utilized by
antibiotics may serve as effective alternatives to antibiotic
therapy. In this report, we describe a novel compound
capable of controlling infections mediated by different,
unrelated bacteria via the induction of host derived
reactive oxygen and reactive nitrogen species. This
compound is comprised of cationic liposome DNA
complexes (CLDC) and crude membrane preparations
(MPF) obtained from attenuated Francisella tularensis Live
Vaccine Strain (LVS). Pretreatment of primary mouse or
human cells limited replication of virulent F. tularensis,
Burkholderia pseudomallei, Yersinia pestis and Brucella
abortus in vitro. CLDC+MPF was also effective for
controlling lethal pulmonary infections with virulent F.
tularensis. Thus, CLDC+MPF represents a novel antimicro-
bial for treatment of lethal, acute, bacterial infections.
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to no intact bacteria present in the cytosol (Figure S2).
Following entry and escape into the host cytosol, SchuS4
undergoes a lag period of approximately 4 hours prior to initiation
of replication. Replication in the primary infected cell then
commences and continues over a 12–18 hour time period [11].
Thus, we next determined at what point after infection CLDC+MPF
could restrict intracellular SchuS4 growth in macrophages, Cultures
treated with CLDC+MPF 4 hours after infection had significantly
fewer infected cells compared to untreated controls (p,0.05) (Figure
S3). In contrast, macrophages treated with CLDC+MPF 12 hours
after SchuS4infectionfailedtocontrolbacterialreplicationcompared
to untreated controls (Figure S3). Together, these data suggested that
in order for CLDC+MPF to exert its protective effects macrophages
must be stimulated at time points prior to intracellular replication of
SchuS4.
Figure 1. CLDC+MPF mediated control of F. tularensis replication in mouse macrophages. Mouse macrophages were treated with D5W
(untreated), MPF, CLDC, or CLDC+MPF 18 h prior to infection. Four, 8, 12 and 24 h after infection phagocytosis and intracellular replication of F. tularensis
was monitored by microscopy. Exposure to CLDC, MPF or CLDC+MPF did not impact the number of cells infected (A and C) nor the number of bacteria
entering each cell (B). MPF and CLDC treatment alone significantly increased the number SchuS4 infected cells 24 h after infection compared to untreated
controls (*=p,0.01) (A and C). In contrast, CLDC+MPF treated cultures had fewer infected cells within 8 h of infection through 24 h after infection
(**=p,0.01) (A and C). White arrows indicate intracellular SchuS4. Data is representative of four experiments. Error bars represent SEM.
doi:10.1371/journal.ppat.1000921.g001
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Stimulation of ROS and RNS in mammalian cells represents an
important mechanism by which the host controls and eliminates
bacterial growth, especially in the intracellular environment (as
reviewed, [12]). Furthermore, ROS and RNS have been
implicated as important mediators for control of attenuated strains
of F. tularensis [13,14,15,16]. Thus, we hypothesized that
CLDC+MPF may be mediating control of SchuS4 infection in
macrophages via induction of ROS and/or RNS. We first
determined if MPF, CLDC, or CLDC+MPF induced expression
of genes associated with oxidative stress. Mouse macrophages
treated with CLDC+MPF had higher expression levels of genes
associated with RNS (nitric oxide synthetase 2) and ROS
(superoxide dismutase 2, NADPH oxidase 1) compared to
Figure 2. CLDC+MPF mediated control of F. tularensis replication in human macrophages. Human macrophages were treated with D5W
(untreated), MPF, CLDC, or CLDC+MPF 18 h prior to infection. Four, 8, 12 and 24 h after infection phagocytosis and intracellular replication of F.
tularensis was monitored by microscopy. Exposure to CLDC, MPF or CLDC+MPF did not impact the number of cells infected (A and C) nor the number
of bacteria entering each cell (B). CLDC+MPF treated cultures had fewer infected cells within 12 h of infection and through 24 h after infection
(*=p,0.01) (A and C). White arrows indicate intracellular SchuS4. Data is representative of four experiments. Error bars represent SEM.
doi:10.1371/journal.ppat.1000921.g002
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genes was highest when cells were treated with CLDC+MPF
rather than CLDC or MPF alone (Figure 3). Similarly, treatment
of human cells with CLDC+MPF resulted in increased expression
of genes associated with generation of ROS, e.g. phox p47,
superoxide dismutase 2, NADPH oxidase, and GTP cyclohydro-
lase, as well as RNS, e.g. and nitric oxide synthase 2A compared to
untreated cells and cells treated with MPF alone (Figure 3).
Interestingly, although CLDC alone failed to control SchuS4
infection in human macrophages, cells treated with this compound
in the absence of MPF had greater gene transcription for three
genes involved in generation of ROS, i.e. superoxide dismutase 2,
phox47 and GTP cyclohydrolase compared to cells treated with
CLDC+MPF (Figure 3). We also compared induction of ROS and
RNS related genes in cells treated with a known inducer of RNS,
IFN-c to CLDC+MPF. CLDC+MPF elicited higher gene
transcription of nitric oxide synthetase (nos2), NADPH oxidase
and superoxide dismutase (sod2) in mouse cells and GTP
cyclohydrolase, nitric oxide synthetase 3 (nos3), NADPH oxidase,
phox 47 and sod2 in human cells than IFN-c (Figure S4).
Induction of both RNS and ROS is often dependent on the
presence of IFN-c, TNF-a, IFN-b and other pro-inflammatory
cytokines. In correlation with the expression levels of RNS and
ROS associated genes, mouse macrophages treated with
CLDC+MPF secreted significantly higher concentrations of
TNF-a compared to cells treated with CLDC or MPF alone
(Figure 4). Addition of MPF to CLDC also increased secretion of
IL-6 and IFN-b from mouse cells compared to cells treated with
CLDC alone, however these differences were not significant
(Figure 4).
We also monitored production of cytokines from human cells
treated with MPF, CLDC or CLDC+MPF. Although no IL-12p40
or IFN-b was detected in any cell culture supernatant,
CLDC+MPF induced secretion of significantly higher concentra-
tions of IL-6 from human macrophages compared to cells treated
with CLDC alone (Figure 4). Human macrophages also produced
significantly higher concentrations of TNF-a in response to CLDC
and CLDC+MPF compared to cells treated with D5W or MPF
(Figure 4). Thus, both CLDC and CLDC+MPF elicited
production of cytokines associated with induction of RNS and
ROS, and in some cases, the combination of CLDC+MPF
resulted in higher concentrations of these cytokines.
CLDC+MPF mediated control of SchuS4 was dependent
on ROS and RNS in vitro
To determine if the induction ROS, RNS or both ROS and
RNS by treatment of cells with CLDC+MPF contributed to
control of SchuS4 infection, we first examined the ability of
CLDC+MPF to limit SchuS4 replication 24 h after infection in
macrophages obtained from mice deficient for both RNS and
ROS. There was not a difference in the percentage of infected cells
among untreated wild type and nos2/gp91
2/2 macrophages,
suggesting that nos2/gp91
2/2 cells were not more susceptible to
SchuS4 infection compared to wild type cells (Figure 5A). As
Figure 3. Induction of RNS and ROS genes by CLDC+MPF. Mouse and human macrophages were treated with D5W, CLDC, MPF or CLDC+MPF.
After 16 and 12 h, respectively, gene expression was monitored by quantitative RT-PCR. Change in the expression of the indicated genes is
represented as fold change over D5W treated controls. Data is representative of three experiments.
doi:10.1371/journal.ppat.1000921.g003
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CLDC+MPF had significantly fewer infected macrophages
compared to untreated cells (p,0.01) (Figure 5A). In contrast,
CLDC+MPF failed to control SchuS4 infection in macrophages
from nos2/gp91
2/2 mice (Figure 5A). Furthermore, pre-treat-
ment of nos2/gp91
2/2 macrophages with CLDC+MPF resulted
in significantly more infected macrophages 24 h after the onset of
the experiment (p,0.01) (Figure 5A). Thus, CLDC+MPF
mediated control of SchuS4 infection was at least partially
dependent on ROS and RNS in mouse macrophages.
Figure 4. CLDC+MPF induced production of pro-inflammatory cytokines in macrophages. Mouse and human macrophages were treated
with D5W (untreated), MPF, CLDC, or CLDC+MPF and 24 h later supernatants were assessed for cytokines by ELISA. In mouse cells, CLDC and
CLDC+MPF induced significantly more IL-6, IL-12 and IFN-b compared to D5W or MPF treated cells (*=p,0.01). Whereas, CLDC+MPF induced
significantly more TNF-a compared to all other groups (**=p,0.01). In human cells CLDC and CLDC+MPF induced significantly more TNF-a
compared to D5W or MPF treated cells (*=p,0.01). Whereas CLDC+MPF induced significantly more IL-6 compared to all other groups (**=p,0.01).
Data is representative of four experiments. Error bars represent SEM.
doi:10.1371/journal.ppat.1000921.g004
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CLDC+MPF mediated control of SchuS4 infection in wild type
mouse macrophages, we conducted additional experiments using
compounds that specifically interfere with either the generation of
RNS (L-NMMA) or ROS (NAC). IFN-c has been shown to
mediate killing of intracellular bacteria, including Francisella,
Figure 5. CLDC+MPF control of F. tularensis is dependent on RNS and ROS. (A) Macrophages from wild type or nos2/gp91
2/2 mice were
treated with D5W (untreated) or CLDC+MPF for 18 h followed by infection with SchuS4. Intracellular replication was monitored by microscopy and
the percent infected cells is depicted for each group. CLDC+MPF significantly reduced the number of SchuS4 infected wild type cells (*=p,0.01),
whereas CLDC+MPF treatment of nos2/gp91
2/2 significantly increased the number of infected macrophages (**=p,0.01). (B and C) Wild type
mouse macrophages were treated with D5W (untreated), IFN-c or CLDC+MPF in the presence or absence of L-NMMA (B) or NAC (C) and then infected
with SchuS4. IFN-c and CLDC+MPF significantly lowered SchuS4 infected cells (*=p,0.05) compared to untreated controls. Addition of L-NMMA and
NAC significantly increased the number of infected macrophages compared to IFN-c (**=p,0.05) or CLDC+MPF (***=p,0.01) treated controls. (D
and E) Human macrophages were treated with D5W (untreated), IFN-c or CLDC+MPF in the presence or absence of L-NMMA (D) or NAC (E) and then
infected with SchuS4. IFN-c and CLDC+MPF significantly lowered SchuS4 infected cells (*=p,0.05) compared to untreated controls. Addition of L-
NMMA significantly increased the number of infected macrophages compared to IFN-c (**=p,0.05), but not CLDC+MPF treated controls. Addition
of NAC significantly increased the number of infected macrophages compared to CLDC+MPF (**=p,0.01), but not IFN-c, treated controls.
doi:10.1371/journal.ppat.1000921.g005
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macrophages pretreated with IFN-c followed by exposure to L-
NMMA or NAC served as positive controls for inhibition of ROS
and RNS species. As expected, pretreatment of mouse and human
macrophages with IFN-c significantly reduced the number of cells
infected with SchuS4 compared to untreated controls (p,0.01)
(Figure 5B–E). The role of both RNS and ROS in IFN-c mediated
control of SchuS4 in mouse macrophages was confirmed by
significant increases in SchuS4 infected cells following addition of
either L-NMMA or NAC to IFN-c treated cells (p,0.05)
(Figure 5B–C). Similarly, addition of L-NMMA or NAC to
CLDC+MPF pretreated mouse macrophages reversed the pro-
tective effect observed with this prophylaxis (Figure 5B–C).
Furthermore, addition of either L-NMMA or NAC to
CLDC+MPF treated cells also appeared to increase the number
of infected cells over untreated controls (Figure 5B–C). Thus, in
mouse macrophages CLDC+MPF mediated killing of SchuS4 was
dependent on the generation of both RNS and ROS.
In contrast to mouse cells, inhibition of RNS had little effect on
the ability of CLDC+MPF to control SchuS4 infection in primary
human macrophages (Figure 5D). Rather, inhibition of ROS
following addition of NAC significantly increased the number of
infected cells among CLDC+MPF treated samples (p,0.05)
(Figure 5E). This suggested that in human macrophages
generation of ROS, rather than RNS, following treatment with
CLDC+MPF was the primary mechanism for control of SchuS4 in
human macrophages.
CLDC+MPF protected against SchuS4 infection in vivo
Macrophages are one of the primary cells targeted by SchuS4
for replication in vivo [17]. The dramatic effect CLDC+MPF had
on control of intracellular growth of SchuS4 in macrophages in
vitro (Figures 1–5) suggested that this compound may be an
effective anti-microbial in vivo. Thus, we next assessed the ability of
CLDC, MPF and CLDC+MPF to protect mice from pulmonary
challenge with SchuS4. Pretreatment of mice with CLDC alone
failed to protect animals from SchuS4 related mortality, regardless
of the route of time at which the CLDC was administered. In fact,
administration of CLDC within 48 hours prior to infection by any
route exacerbated disease, as indicated by an increase in the mean
time to death of treated animals compared to untreated controls
(Table 3). In contrast, administration of CLDC intravenously,
intranasally or intraperitoneally 72 hours prior to infection
modestly increased the mean time to death (,0.2 days) (Table 3).
Thus, as observed among in vitro stimulated macrophages, CLDC
did alone did not protect animals for death following SchuS4
infection.
Administration of CLDC three days prior to challenge resulted
in a minor increase in mean time to death. Furthermore,
treatment of animals prior to that time point resulted in
exacerbated disease. Thus, we chose to examine the protective
efficacy of CLDC+MPF in animals treated three days prior to
infection. The results of these studies are depicted in Table 4.
Administration of CLDC+MPF intranasally failed to protect or
improve survival of SchuS4 infections. Twenty percent of animals
treated with CLDC+MPF subcutaneously or intraperitoneally
survived SchuS4 infection. Additionally, animals treated via these
routes that succumbed to infection survived longer than untreated
controls. Animals treated with CLDC+MPF intravenously had the
greatest survival rate, with approximately 50% of these animals
surviving SchuS4 infection (Table 4 and Figure 6A). Intravenous
injection of either CLDC or MPF failed to protect animals from
succumbing to infection (Table 4). Furthermore, intravenous
injection of CLDC+MPF 1,2 or 7 days prior to infection failed to
protect animals against SchuS4 (data not shown). Thus, in vivo
protection against SchuS4 required CLDC and MPF delivered
three days prior to infection.
Previous studies have shown that LVS LPS can protect mice
from lethal LVS infections [18,19,20,21,22]. MPF contains LVS
LPS. Thus, we postulated that LVS LPS present in MPF may
represent an important immunogen for conferring the protection
observed in CLDC+MPF treated mice. To test this hypothesis,
mice were injected intravenously with LPS purified from LVS
alone or in combination with CLDC. Surprisingly, neither LVS
Table 3. CLDC alone does not protect against pulmonary F.
tularensis SchuS4 infections
a.
Treatment Route
Time Before
Challenge
(hours)
Survivors/
Total
Mean Time to
Death
(MTD) ±SEM
untreated - - 0/10 5.860.133
CLDC
b IV
c 24 0/10 5.060.000
48 0/10 5.060.000
72 0/10 6.060.000
CLDC IP
d 24 0/10 5.460.163
48 0/10 4.060.000
72 0/10 6.060.000
CLDC IN
e 24 0/10 4.660.163
48 0/10 4.860.133
72 0/10 6.060.000
CLDC SC
f 24 0/10 5.260.133
48 0/10 5.060.000
72 0/10 4.760.213
aBalb/c mice were challenged intranasally with 25 CFU F. tularensis SchuS4.
bCationic DNA Liposome Complexes,
cintravenous,
dintraperitoneal,
eintranasal,
fsubcutaneous.
doi:10.1371/journal.ppat.1000921.t003
Table 4. Effect of delivery route and antigen on CLDC+MPF
mediated protection against F. tularensis SchuS4
a.
Treatmentb Route Survivors/Total
Mean Time
to Death
(MTD) ±SEM
untreated - 0/5 5.460.400
CLDC+MPF
c IV
d 6/10 8.060.000
IP
e 2/10 6.560.267
IN
f 0/10 6.060.000
SC
g 2/10 7.160.398
CLDC IV 0/10 6.260.112
MPF IV 0/10 4.860.200
LVS LPS IV 0/10 5.460.245
SchuS4 LPS IV 0/10 5.860.200
CLDC+LVS LPS IV 0/10 8.060.000
CLDC+SchuS4 LPS IV 0/10 7.860.200
aBalb/c mice were challenged intranasally with 25 CFU F. tularensis SchuS4.
bMice were treated 3 days prior to challenge,
cCationinc DNA Liposome
Complexes,
dintravenous,
eintraperitoneal,
fintranasal,
gsubcutaneous.
doi:10.1371/journal.ppat.1000921.t004
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SchuS4 infection (Table 4). However, LVS LPS in CLDC did
increase the mean time to death by approximately 2 days
compared to untreated controls (Table 4). This suggested that
LVS LPS combined with CLDC was able to stimulate the host
immune response for minimal control of SchuS4 infection.
Although LPS from LVS and SchuS4 do not elicit strong
production of pro-inflammatory cytokines, it was possible that
there might be other differences in the immunostimulating
potential of these two LPS molecules that would only be revealed
in vivo [23,24,25]. Thus, we also compared protective efficacy of
SchuS4 LPS to protect against SchuS4 infection. Similar to LVS
LPS, mice treated with SchuS4 LPS were not protected from
death (Table 4). However, inclusion of CLDC did modestly
increase the mean time to death in SchuS4+CLDC treated
animals (Table 4). Together, these data suggest that Francisella
LPS was not the major component of MPF mediating protection
against SchuS4 infection in CLDC+MPF treated animals.
Given the importance of both ROS and RNS in CLDC+MPF
mediated control of SchuS4 infection in mouse macrophages in
vitro, we also assessed the role of these antimicrobial host
components in vivo. Pretreatment of mice with CLDC+MPF
protected significantly more wild type animals from SchuS4
compared to untreated controls (p=0.0027) (Figure 6B). In
contrast to the protection observed in wild type animals,
CLDC+MPF did not significantly increase the number of
surviving nos2/gp91
2/2 compared to untreated controls
(p=0.3173) (Figure 6B). Furthermore, untreated nos2/gp91
2/2
mice were not more susceptible to SchuS4 infection compared to
untreated wild type mice. This suggested that the lack of
protection observed in CLDC+MPF treated nos2/gp91
2/2 was
not due to inherent lack of resistance to F. tularensis in these
animals. Rather, our data suggests that in the absence of intact
pathways for generation of ROS and RNS CLDC+MPF activates
cells that render them more susceptible to infection. These results
further underscore the importance of induction of ROS and RNS
in F. tularensis infections. Together this data confirmed that
protection mediated by CLDC+MPF was dependent on stimula-
tion of pathways associated with oxidative stress in vivo.
CLDC+MPF protected against multiple bacterial
pathogens
Previous experiments have shown that CLDC alone is an
effective prophylaxis against B. pseudomallei and attenuated strains
of Francisella [26,27]. However, CLDC alone failed to protect
against virulent Francisella and Y. pestis ([27] and CM Bosio,
unpublished data). As shown above, compared to CLDC alone,
CLDC+MPF provided superior protection against virulent
Francisella (Table 1 and 2; Figures 1 and 2). Thus, it was possible
that the combination of CLDC and antigen may also effectively
control infections mediated by other, unrelated pathogens.
Furthermore, the ability of CLDC or CLDC+MPF to control
bacterial infections in human cells has not been examined. To
assess the anti-bacterial capabilities of CLDC+MPF, we pretreated
human macrophages with CLDC+MPF, infected them with B.
pseudomallei, Y. pestis or B. abortus, and evaluated bacterial
replication over time. As previously observed with CLDC alone
in mouse cells, CLDC+MPF controlled both the number of B.
pseudomallei infected human macrophages and replication of
intracellular bacteria within 6 h of infection (Figure 7). Surpris-
ingly, CLDC+MPF also reduced the number of cells infected with
Y. pestis at 2 and 6 h after infection and B. abortus 24 h after
infection (Figure 7). Furthermore, treatment of cells with
CLDC+MPF inhibited the intracellular replication of both Y.
pestis and B. abortus (Figure 7). Together this data suggests that,
unlike CLDC alone, stimulation of cells with CLDC+MPF can aid
in the control of several different, unrelated, virulent bacteria.
Discussion
The discovery of antibiotics as broad spectrum chemothera-
peutics for bacteria greatly enhanced our ability to fight off and
control bacterial diseases. However, commiserate with the general
use of antibiotics, bacteria have responded by developing
resistance to these important and ubiquitous compounds. One
strategy employed to enhance resistance against microbial
pathogens is to directly stimulate the host immune response and
allow natural, host mediated, killing mechanisms to control
microbial infections. These novel immunotherapeutics could be
used independently or in context of antibiotic therapy to aid in
clearance of bacteria. In turn this would allow for a decrease the
amount of time antibiotics should be administered, an increase in
the time before antibiotics must be administered, and/or lower
dosages of antibiotics required for complete clearance of the
bacterium.
Here we describe a novel, broad spectrum antimicrobial
immunoprophylaxis consisting of cationic DNA liposome com-
plexes (CLDC) and crude membrane preparations (MPF) derived
from F. tularensis that effectively limited replication of virulent F.
tularensis, B. pseudomallei, Y. pestis and B. abortus in human and mouse
macrophages in vitro. Importantly, administration of CLDC+MPF
prior to pulmonary infection with F. tularensis also contributed to
survival in mice. The mechanism of protection mediated by
CLDC+MPF was, in part, dependent on the induction of reactive
oxygen and nitrogen species in vivo and in vitro.
Previous reports have shown that either CpG oligodeoxynu-
cleotides (ODN) or CLDC alone can protect against lethal
infections with attenuated strains of F. tularensis, e.g. LVS
[27,28,29]. However, neither of these therapeutics have been able
to protect animals from death following SchuS4 infection [27,29].
We confirmed and extended these results by demonstrating that
regardless of the route of time CLDC was administered prior to
challenge, this reagent could not decrease the number of
mortalities among SchuS4 infected mice. In fact, in our hands
injection of CLDC 1 or 2 days prior to SchuS4 challenge
exacerbated disease as indicated as a decrease in the mean time to
death (Table 3). Our results do slightly differ from those reported
by Troyer et al, but are closer in agreement with the report by
Rozak et al in which administration of CpG ODN less than
24 hours prior to infection exacerbated disease [27,29]. In the
experiments reported by Troyer et al., addition of DNA to cationic
liposomes was performed under standard laboratory conditions
with no obvious means to monitor quality control. Further, there
was no indication of endotoxin levels present in the preparations of
DNA. Addition of other TLR agonists to cationic liposomes
enhances their immunogenicity [30]. Thus, contaminating
endotoxin could have increased and/or changed the inflammatory
response in the Troyer study resulting in a different mean time to
death. The CLDC used in the study presented herein were
produced under strict GMP laboratory conditions and underwent
a battery of quality control assays prior to use to insure consistency
from lot to lot. Thus, it is possible that minor variations in CLDC
preparations used in the Troyer study could account for the 1.4
day extension in mean time to death among SchuS4 infected mice.
It is not clear why CLDC exacerbated infection in vitro and in
vivo. One possibility is that activation of macrophages with CLDC
increases their phagocytic capability without eliciting effective
killing mechanisms. Indeed, immediately after infection CLDC
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to untreated cells (p,0.05) (Table 2). MPF alone also activates
macrophages and increased uptake of SchuS4. Thus, it is possible
that the exacerbation of infection observed in macrophages treated
with either CLDC or MPF alone may be a direct result of
increased phagocytosis in the absence of effective killing.
In contrast to exacerbation of infection in mice treated with
CLDC alone, we observed a small increase in the mean time to
death among animals treated with CLDC alone 3 days prior to
infection (Table 3). Similarly, CpG has been noted to increase the
mean time to death of SchuS4 infected mice by 1 day if delivered 2
days prior to infection [29]. This suggested CLDC and CpG alone
could contribute toward controlling SchuS4 infection when
delivered at the appropriate time before infection. CLDC does
contain CpG ODN sequences. However, these sequences are not
required for CLDC to exert protective effects against infections in
vivo [7]. The induction of inflammatory responses by CLDC
which do not contain CpG motifs may be attributed to cellular
recognition of bacterial DNA. Although TLR9 represents an
important receptor for recognition of CpG motifs present in
bacterial DNA, it is not the only host receptor capable of detecting
prokaryotic DNA. For example, DAI is a cytosolic receptor
Figure 6. CLDC+MPF enhanced survival of SchuS4 infection in vivo. (A) Mice (n=10 per group) were treated with CLDC+MPF i.v. 3 days prior
to intranasal challenge with SchuS4. Significantly more CLDC+MPF treated mice survived infection compared to untreated controls (p=0.0027). (B)
Wild type (WT) or nos2/gp91
2/2mice (n=5 per group) were treated with CLDC+MPF 3 days prior to challenge with SchuS4. Sixty percent of
CDLC+MPF treated WT mice survived infection, whereas significantly fewer nos2/gp91
2/2 survived (p=0.0385). Data are representative of two
experiments.
doi:10.1371/journal.ppat.1000921.g006
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motifs and can trigger immune responses in mammalian cells in a
TLR9 independent manner [31]. Thus, the immunogenicity of
CLDC cannot be completely attributed to the presence of CpG.
One of the major components of MPF is LPS. LPS from LVS
lacks properties typically associated with endotoxin, e.g. stimula-
tion of pro-inflammatory cytokines (25). However, injection of
LVS LPS can protect animals from lethal LVS infections. Thus,
we tested LPS from both LVS and SchuS4 for protective efficacy
against pulmonary tularemia. Surprisingly, neither LPS prepara-
tion was able to protect animals from death following intranasal
SchuS4 infection (Table 4). Administration of Francisella LPS in
CLDC did modestly increase the mean time to death in SchuS4
infected animals, but these animals eventually succumbed to
infection (Table 4). This suggested that Francisella LPS alone is
not the bacterial antigen contributing to the protective effects of
CLDC+MPF. Another bacterial ligand that may contribute to the
protective efficacy of CLDC+MPF is peptidoglycan or one of its
precursors, i.e. muramyl dipeptide (MDP) or tracheal cytotoxin
(TCT). Both MDP and TCT can contribute toward the induction
of nitric oxide [32,33,34,35,36]. Interestingly, MDP typically
requires cells to be primed with IFN-c or other immunostimulants
in order to induce nitric oxide [35,36]. We have not quantitated
MDP or TCT present in our MPF preparations. However, it is
tempting to speculate that either or both of these compounds may
contribute to the protective efficacy of CLDC+MPF.
In both the in vitro and in vivo models pre-stimulation of
macrophages before replication of SchuS4 began was required
for killing of bacteria. In vitro, cells stimulated with CLDC+MPF
12 h after infection failed to significantly control Francisella
replication (Figure S3). Similarly, administration of
CLDC+MPF less than three days prior to pulmonary challenge
failed to protect animals from lethal disease (CM Bosio,
unpublished data). There are several explanations for this pre-
stimulation requirement. First, the kinetics of SchuS4 intracel-
lular replication on the level of individual cells following in vivo
infection has not been defined. It is possible that following
infection of macrophages in vivo SchuS4 does not undergo a lag
Figure 7. CLDC+MPF mediated protection against unrelated bacterial pathogens. Human macrophages were untreated (D5W) or treated
with CLDC+MPF 18 h prior to infection followed by infection with B. pseudomallei, Y. pestis or B. abortus, At the indicated time points cells were
analyzed for intracellular bacteria by microscopy. CDLC+MPF significantly reduced the number of infected cells and the number of bacteria per cell
regardless of the species of infecting bacteria (*=p,0.05). Data is representative of three experiments. Error bars represent SEM.
doi:10.1371/journal.ppat.1000921.g007
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infected macrophages. Second, SchuS4 targets multiple cell
types in vivo. In addition to macrophages, this bacterium also
infects dendritic cells and epithelial cells at the outset of
infection [37,38]. It is not known if CLDC+MPF activates
dendritic cells and epithelial cells in the same manner we have
observed in macrophages. Longer stimulation of these cells may
be required for adequate priming of killing mechanisms in these
and/or neighboring cells.
The third possibility may be a requirement for activation of
other host effector cells or molecules. It has been suggested that
NK cells contribute to eradication of F. tularensis following
pulmonary infections [39]. Interestingly, intravenous injection of
CLDC results in accumulation of NK cells in the lungs which
peaks three days after injection [40]. Data from our laboratory
suggests that SchuS4 specific NK cells present in lungs of
vaccinated mice are capable of controlling SchuS4 replication in
this tissue (CM Bosio and RV Anderson, unpublished data). Thus,
injection of CLDC+MPF three days prior to infection may allow
the accumulation of SchuS4 specific NK cells capable of restricting
bacterial replication in the lungs.
The requirement for pre-stimulation may also lie in the amount
of time necessary for ROS and RNS to be activated. F. tularensis
encodes genes that specifically interfere with production of reactive
oxygen and nitrogen species [41]. In the absence of pre-activation,
RNS and ROS generation in host macrophages is efficiently
impeded by virulent F. tularensis [41]. Similarly, interference with
induction of RNS and ROS as a mechanism to evade killing has
also been reported for Y. pestis and B. pseudomallei [42,43]. Thus,
generation of adequate RNS and ROS by hosts cells prior to
infection or replication of bacteria if host cells would be required
for optimal control of infections with these virulent bacteria.
An additional explanation for the necessity of pre-stimulation of
host cells lies in the mechanism by which RNS and ROS are
generated. Reactive oxygen and nitrogen species are most
effectively produced in response to several pro-inflammatory
cytokines. For example, although neither TNF-a nor IFN-b can
act alone to induce release of nitric oxide or hydrogen peroxide,
these cytokines act synergistically with bacterial antigens to
augment production of these two antimicrobial compounds [44].
Our data demonstrate that CLDC, and in some cases
CLDC+MPF, induced significantly more TNF-a and IFN-b
compared to untreated cells or cells exposed to MPF alone
(Figure 4). Thus, it is possible that optimal stimulation of RNS and
ROS was dependent on the generation of these, and perhaps
other, proinflammatory cytokines which would require additional
time for generation of ROS and RNS prior to infection.
Another important observation made in the studies presented
herein was that the putative roles for ROS and RNS for control of
F. tularensis were dramatically different in mouse and human
macrophages. As described above, CLDC+MPF mediated killing
in mouse macrophages was dependent on the generation of ROS
and RNS (Figure 5A–C). This is in agreement with previous
reports describing the contribution of these species for control of
more attenuated strains of F. tularensis [15,41,45]. However, in
human macrophages inhibition of RNS had no effect on the
antibacterial activity mediated by CLDC+MPF on F. tularensis
(Figure 5D and E). Rather, generation of ROS was essential for
CLDC+MPF mediated killing of F. tularensis. In the past it was
commonly believed that human cells could not produce RNS.
Thus, one might assume that the dependency on ROS for
CLDC+MPF mediated killing in human cells was due to an
inherent inability of these macrophages to generate RNS. Indeed,
soon after the description of cytokine induced nitric oxide in
mouse cells, investigators attempted to reproduce the phenomenon
in human macrophages. However, early studies in human cells did
not recapitulate the potent nitric oxide response observed in
mouse macrophages [46]. This led to the hypothesis that human
cells did not express the product responsible for cytokine induced
nitric oxide, iNOS. Since those early studies there have been a
number of reports demonstrating the presence and function of
iNOS in human cells [47]. We now understand that the inability of
human macrophages to produce nitric oxide in response to
cytokines alone was due to the nature of the cell type (as reviewed,
[48]). For example, macrophages differentiated in vitro from
resting peripheral blood monocytes of normal donors generally do
not express iNOS. In contrast, macrophages differentiated from
monocytes obtained from donors with chronic inflammatory
disorders or currently battling infection readily express iNOS
[49,50]. Thus, under the appropriate conditions human macro-
phages, like mouse macrophages can induce RNS. As shown in the
present manuscript, IFN-c induced RNS is capable of controlling
SchuS4 replication in human macrophages, thus confirming the
ability of human cells to generate effective RNS responses.
Therefore, the role for ROS in CLDC+MPF mediated killing of
SchuS4 in human macrophages is not due to the inability of the
cells to generate RNS, but is a unique feature of CLDC+MPF
stimulation of this cell type.
Understanding and identifying the different requirements and
redundancy for RNS and ROS in mouse and human cells is
important for several reasons. First, identification of the mecha-
nisms by which human and mouse cells control infections with
virulent bacteria is essential for monitoring the potential
effectiveness of novel drugs. Second, identification of the specific
killing pathways will also aid in development of other novel
therapeutics. Lastly, understanding the different requirements for
bacterial killing in human and mouse macrophages may reveal
new pathways used by host cells to effectively combat invading
pathogens. As described above, unlike stimulation with IFN-c,
CLDC+MPF revealed a difference in the mechanism by which
human and mouse macrophages control virulent F. tularensis.
Thus, this reagent may also serve as a useful tool to dissect the
relative roles of these pathways in the effective control of infections
with virulent bacteria. This in turn may result in superior
immunoprophylaxis and therapeutics for infections mediated by
diverse groups of bacteria.
Materials and Methods
Ethics statement
Human blood cells were collected from anonymous volunteers
under a protocol reviewed and approved by the NIH Clinical
Center Institutional Review Board. Signed, informed consent was
obtained from each donor acknowledging that their donation
would be used for research purposes by intramural investigators
throughout NIH.
Bacteria
Francisella tularensis strain SchuS4 was kindly provided by
Jeannine Peterson, Ph.D. (Centers for Disease Control, Fort
Collins, Colorado), F. tularensis strain LVS was provided by Jean
Celli, Ph.D. (Rocky Mountain Laboratories, Hamilton, Montana).
SchuS4 and LVS were cultured in modified Mueller-Hinton
(MMH) broth at 37uC with constant shaking overnight, aliquoted
into 1 ml samples, frozen at 280uC and thawed just prior to use as
previously described [37]. Frozen stocks were titered by enumer-
ating viable bacteria from serial dilutions plated on modified
Mueller-Hinton agar as previously described [51,52]. The number
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10 month period.
Yersinia pestis strain 195/P expressing GFP was provided by B.
Joseph Hinnebusch, Ph.D. (Rocky Mountain Laboratories,
Hamilton, Montana). 195/P-GFP was cultured overnight at
21uC in BHI broth followed by subculture at 37uC as previously
described [43]. Bacterial titer was estimated by optical density of
the culture at 600nm. Inoculum titers were confirmed following
enumeration of viable bacteria from serial dilutions plated on
blood agar plates as previously described [43].
Burkholderia pseudomallei strain DD503 expressing GFP was
provided by David DeShazer, Ph.D. and Mary Burtnick, Ph.D.
(USAMRIID, Fort Detrick, MD and University of South
Alabama, Mobile AL, respectively). DD503-GFP was cultured in
LB broth overnight at 37uC. Three hours before use, DD503-GFP
was diluted 1:25 in TSBDC culture medium [53] and incubated at
37uC. Bacterial titer was estimated by optical density of the culture
at 600nm. Immediately prior to use bacteria were diluted in tissue
culture medium and added to cells as described below. Inoculum
titers were confirmed following enumeration of viable bacteria
from serial dilutions plated on LB agar as previously described
[54].
Brucella abortus strain 2308 expressing GFP was kindly supplied
by Jean Celli, Ph.D. (Rocky Mountain Laboratories, Hamilton,
MT). GFP-B. abortus was cultured on Tryptic Soy agar (TSA)
plates for 48 h at 37uC. Individual colonies were then transferred
to Tryptic Soy Broth (TSB) and bacteria were cultured overnight
at 37uC with constant shaking. The number of bacteria present on
broth cultures was determined by OD 600nm. Actual numbers of
viable bacteria were confirmed by plating an inoculum on TSA
plates as previously described [55].
Generation of MPF, LPS and CLDC+MPF
LVS was grown in MMH broth as described above. Following
overnight culture, LVS was centrifuged for 15 minutes at 80006g.
The resulting pellet was resuspended in breaking buffer (50 mM
Tris/HCl, 0.6 mg/ml DNase, 0.6 mg/ml RNase, 1 mM EDTA
[all from Sigma] and 1 Complete EDTA free tablet [Roche]) and
the bacteria were centrifuged again for 15 minutes at 80006g.
Pelleted bacteria were then resuspended in breaking buffer. To
break open LVS, the bacteria were added to Fast Prep Lysing
Matrix B tubes and processed in a FastPrep24 (MPBio) for 10
cycles of 45 seconds with 2 minute rest periods on ice in between
each cycle. The resulting slurry was then centrifuged at
10,000 rpm for 10 minutes. The supernatant was collected and
centrifuged twice at 100,0006g for 4 h. The pellet was
resuspended in buffer containing 50 mM Tris/HCl, 1 mM EDTA
and dialyzed against PBS using 3000 MW cutoff Slide-A-Lyzer
cassettes (Pierce). Protein concentration of LVS membrane protein
fraction (MPF) was determined using a BCA Protein Assay
Reagent Kit according to the manufacturer’s instructions.
Endotoxin levels were determined using Limulus Amebocyte
Lysate (LAL) assay. Endotoxin levels were ,0.1 EU/mgo f
protein. MPF was then aliquoted, irradiated to render it sterile,
and stored at -80uC. SchuS4 LPS was generated as previously
described [23]. LVS LPS was obtained from the BEI Resources
(Manassas, VA).
CLDC was provided by Juvaris Biotherapeutics. Formulation of
CLDC has been previously described [56]. CLDC was prepared
by Juvaris Therapeutics under good manufacturing conditions
(GMP). Briefly, DOTIM:cholesterol liposomes were combined to
form a liposome intermediate. pMB75.6 plasmids were generated
from the non-pathogenic strain of E. coli DH5a. The plasmid
contains the following elements: (i) the cytomegalovirus immediate
early (CMV-IE) promoter/enhancer, (ii) a polyadenylation signal
derived from simian virus 40 (SV40), (iii) a kanamycin-resistance
gene, and (iv) an origin of replication (pUCori/f1ori). There are no
genes expressed by the plasmid. pMB75.6 plasmids were added to
liposomes at a ratio of 9.8:1 (lipid:DNA). CLDC were aliquoted,
lyophilized, and stored at 4uC. Endotoxin levels were determined
using Limulus Amebocyte Lysate (LAL) assay. Endotoxin levels of
CLDC were ,0.1 EU/mg DNA.
Immediately prior to use, CLDC was hydrated using 500 ml
endotoxin free, water (Cape Cod Associates Incorporated, E.
Falmouth, MA). CLDC were allowed to rehydrate for approxi-
mately 5 minutes at room temperature. CLDC were then diluted
1:3 in 5% dextrose water (D5W; Baxter Healthcare, Deerfield, IL).
For in vitro experiments, MPF was thawed, vortexed and added to
CLDC at a final concentration of 3.52 mg/ml. As indicated, MPF
and CLDC were also tested individually. In these experiments
MPF was diluted in 5% dextrose water to 3.52 mg/ml. All CLDC,
MPF and CLDC+MPF mixtures were added to cells in a volume
of 50 ml/well and were used immediately following preparation.
For in vivo experiments, MPF or LPS was thawed, vortexed, and
diluted in 5% dextrose water. In experiments testing MPF or LPS
alone, MPF and LPS were diluted to 50 mg/ml. In experiments
testing combination of CLDC and MPF or LPS, the reagents were
added to CLDC at a final concentration of 50 mg/ml. In these
experiments MPF was diluted in 5% dextrose water to 50 mg/ml.
All CLDC, MPF and CLDC+MPF mixtures were used immedi-
ately following preparation. Mice were injected with 200 mlo f
prepared CLDC+MPF.
Culture of bone marrow derived macrophages
Bone marrow derived macrophages were generated as previ-
ously described [51] with the exception that cells were differen-
tiated into macrophages in tissue culture plates with or without
glass coverslips in the presence of 10 ng/ml recombinant murine
M-CSF (Peprotech, Rocky Hill, NJ). All cells were used on day 6
of culture.
Generation of human monocyte derived macrophages
Human monocyte derived macrophages were differentiated
from apheresed peripheral bloo dm o n o c y t e sa sp r e v i o u s l y
described [57]. Briefly, apheresed monocytes were enriched
using Ficoll-paque (GEH e a l t h c a r e ) .C D 1 4
+ progenitor cells
were enriched via negative selection using Dynabeads MyPure
Monocytes Kit for untouched human cells per manufacturer’s
instructions (Invitrogen). Cells were resuspended at 3610
5/ml
in cRPMI supplemented with 10 ng/ml M-CSF (Peprotech)
plated at 1 ml/well in 24-well plates with or without glass
coverslips and incubated at 37uC/5%CO2.O nd a y2a n d5o f
culture medium was replaced with cRPMI supplemented with
10 ng/ml M-CSF. All cells were used on day 6 of culture.
Human blood cells were collected from anonymous volunteers
under a protocol reviewed and approved by the NIH Clinical
Center Institutional Review Board. Signed, informed consent
was obtained from each donor acknowledging that their
donation would be used for research purposes by intramural
investigators throughout NIH.
Treatment and infection of macrophages
Macrophages were treated with CLDC, MPF or CLDC+MPF,
prepared as described above, 18 h prior to infection with bacteria.
As indicated, 1 or 6 hr prior to addition of CLDC+MPF human
and mouse macrophages were pretreated with 10 mM (human) or
3 mM (mouse) N-acetyl-L-cysteine (NAC) (Sigma), 3 mM (human)
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monoacetate (L-NMMA), (Caymen Chemicals), respectively.
Following treatments described above, macrophages were
infected with either F. tularensis SchuS4 (MOI=50), B. abortus
(MOI=50), B. pseudomallei (MOI=1), or Y. pestis (MOI=2).
Briefly, medium was removed and reserved, and then F. tularensis
was co-incubated with macrophages at 37uCi n7 %C O 2 for 1.5 h
followed by treatment with gentamicin (Invitrogen) at 500 mg/ml
for 1 h. Then, cultures were washed extensively and reserved
medium was replaced. The infection inoculum was confirmed by
plating serial dilutions of stock F. tularensis on MMH agar plates
immediately prior to addition to cell cultures.
B. pseudomallei was co-incubated with macrophages at 37uCi n
5% CO2 for 1 h followed by addition of kanamycin (Invitrogen) at
250 mg/ml for the remainder of the experiment.
Y. pestis was co-incubated with macrophages at 21uCi n5 %C O 2
for 1 h followed by treated with gentamicin at 80 mg/ml for 1 h.
Then, cultures were washed extensively and reserved medium
supplemented with 8 mg/ml gentamicin was replaced.
Macrophages were infected with B. abortus as previously
described [55]. At the indicated time points, cells were either
lysed for enumeration of intracellular bacteria or isolation of
RNA, or were fixed with 3% paraformaldehyde in PBS for
20 min at 37uC/5%CO2 prior to analysis for bacteria as
described below.
Enumeration of bacteria
At the indicated time points, medium was removed and cells
were washed extensively. Then, cells were lysed following
incubation in sterile water. Cell lysates were immediately serially
diluted and plated on either MMH, LB, blood, or TSA agar
plates. Agar plates were incubated at 37uC/7% CO2 for 48–72 h
for enumeration of bacterial colonies.
Fluorescence microscopy
Macrophages were grown on coverslips, treated, and infected
with SchuS4, GFP-B. pseudomallei, GFP-Y. pestis or GFP-B. abortus
as described above. Cells were fixed in 3% paraformaldehyde for
20 minutes at 37uC/5%CO2. Cells were washed with PBS and
stained for LAMP-1 as previously described [10,57]. SchuS4 was
detected using Alexa Fluor488 goat conjugated anti-F. tularensis
(US Biological, Swampscot, MA) as previously described [57].
Samples were observed on a Carl Zeiss (Thornwood, NY) Axio
Imager.M1 epifluoresence microscope for quantitative analysis.
Approximately 75–100 cells/field and a minimum of three fields
per coverslip were analyzed for presence of intracellular bacteria.
Percent of infected cells was calculated as follows: (number
infected cells/total number of cells) 6100.
Confocal images of 1,02461,024 pixels were acquired and
assembled using Adobe Photoshop CS2 software (Adobe Systems,
San Jose, CA).
Quantitative PCR analysis
RNA was isolated and converted to cDNA using RT
2 qPCR
Grade RNA Isolation Kit and RT
2 First Strand Kit (both from SA
Biosciences, Frederick, MD) according to manufacturer’s instruc-
tions. Samples were assessed for ROS and RNS associated genes
expression using nitric oxide RT
2 Profiler PCR Arrays for mouse
and human per manufacturer’s instructions (SA Biosciences).
Gene expression was quantitated using RT
2 Profiler PCR Array
Data Analysis Software (SA Biosciences). Accession numbers for
genes in which expression was increased or decreased compared to
untreated controls are listed in Table S1.
Mice
Specific-pathogen-free, 6–8 week old male C57Bl/6 mice (wild
type) (n=10/group) were purchased from Jackson Laboratories
(Bar Harbor, MI). nos2/phox gp91 deficient mice (nos2/gp91
2/2)
mice were bred at the NIAID/Rocky Mountain Laboratories. All
research involving animals was conducted in accordance with
Animal Care and Use guidelines and animal protocols were
approved by the Animal Care and Use Committee at RML.
Treatment and infection of mice
CLDC, MPF and CLDC+MPF were prepared as described
above. At the time points indicated, mice were injected
intravenously (i.v.), intraperitoneally (i.p.) or subcutaneously (s.c.)
with 200 ml of each preparation prior to challenge. For intranasal
(i.n.) administration mice were anesthetized via intraperitoneal
injection with 100 ml of ketamine (12.5 mg/ml) + xylazine
(3.8 mg/ml) solution and the reagents were delivered in a total
volume of 25 ml evenly distributed between the nares at the
indicated time points prior to challenge. Then, mice were
anesthetized via intraperitoneal injection with 100 ml of ketamine
(12.5 mg/ml) + xylazine (3.8 mg/ml) solution and intranasally
infected with 25 CFU SchuS4 diluted in a final volume of 25 mlo f
PBS. Inoculating doses were confirmed by plating inoculum on
MMH agar. This inoculum routinely results in 100% mortality
and a mean time to death of 5 days following infection in naive
animals.
Statistical analysis
For in vitro studies, statistical differences between two groups
were determined using an unpaired student t test with the
significance set at p,0.05. For comparison between three or more
groups, analysis was done by one-way ANOVA followed by
Tukey’s multiple comparisons test with significance determined at
p,0.05. For in vivo studies, significance in survival was assessed
using log-rank (Mantel Cox) test with significance set at p,0.05.
Supporting Information
Figure S1 CLDC+MPF does not induce cell death. Macro-
phages were treated with D5W (untreated), CLDC, MPF or
CLDC+MPF as described in Figure1. Eighteen hours after
treatment cell death was assessed by uptake of trypan blue.
CLDC+MPF did not induce cell death that was significantly
different from untreated, CLDC or MPF treated controls. Data is
representative of three experiments of similar design. Error bars
represent SEM.
Found at: doi:10.1371/journal.ppat.1000921.s001 (1.00 MB TIF)
Figure S2 CLDC+MPF elicits degradation of SchuS4 in
macrophages. Human macrophages were treated with D5W or
CLDC+MPF and were either left uninfected (A and D) or infected
with SchuS4 (B–C and E–F) as described in Figure 1. Twenty-four
hours after infection cells were prepared for analysis by
transmission electron microscopy. Following infection, D5W
treated cells contained intact SchuS4 (B and C) whereas vacuoles
present in CLDC+MPF treated cells consisted predominantly of
degraded bacteria (E and F). White arrows indicated bacteria. C
and F are the magnified areas indicated by the black box in B and
E, respectively. A, B, D, and E are depicted at 40006
magnification. C and F are depicted at 120006 magnification.
Data is representative of two experiments of similar design.
Found at: doi:10.1371/journal.ppat.1000921.s002 (2.04 MB TIF)
Figure S3 CLDC+MPF controls SchuS4 replication when
added within 12 hours of infection. Human macrophages were
Rapid Immunity agaist Virulent Bacteria
PLoS Pathogens | www.plospathogens.org 14 May 2010 | Volume 6 | Issue 5 | e1000921treated with D5W (untreated) or CLDC+MPF 18 h prior to
infection (218), 4 h after infection (+4) or 12 h after infection
(+12). Twenty four hours after infection intracellular replication of
F. tularensis was monitored by microscopy. *=p,0.001 com-
pared to D5W and +12 h treated cells. Data is representative of
two experiments of similar design. Error bars represent SEM.
Found at: doi:10.1371/journal.ppat.1000921.s003 (0.07 MB TIF)
Figure S4 Induction of RNS and ROS genes by IFN-gamma
and CLDC+MPF. Mouse and human macrophages were treated
with D5W, IFN-gamma or CLDC+MPF. After 12 h gene
expression was monitored by quantitative RT-PCR. Change in
the expression of the indicated genes is represented as fold change
over D5W treated controls.
Found at: doi:10.1371/journal.ppat.1000921.s004 (0.05 MB TIF)
Table S1 Gene accession numbers.
Found at: doi:10.1371/journal.ppat.1000921.s005 (0.01 MB
DOCX)
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